ATE309375T1 - Onkostatin- m rezeptor - Google Patents

Onkostatin- m rezeptor

Info

Publication number
ATE309375T1
ATE309375T1 AT95920626T AT95920626T ATE309375T1 AT E309375 T1 ATE309375 T1 AT E309375T1 AT 95920626 T AT95920626 T AT 95920626T AT 95920626 T AT95920626 T AT 95920626T AT E309375 T1 ATE309375 T1 AT E309375T1
Authority
AT
Austria
Prior art keywords
oncostatin
receptor
rbeta
osm
onkostatin
Prior art date
Application number
AT95920626T
Other languages
English (en)
Inventor
Bruce Mosley
David J Cosman
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE309375T1 publication Critical patent/ATE309375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT95920626T 1994-05-26 1995-05-22 Onkostatin- m rezeptor ATE309375T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24955394A 1994-05-26 1994-05-26
US08/308,881 US5783672A (en) 1994-05-26 1994-09-12 Receptor for oncostatin M
PCT/US1995/006530 WO1995033059A2 (en) 1994-05-26 1995-05-22 Receptor for oncostatin m

Publications (1)

Publication Number Publication Date
ATE309375T1 true ATE309375T1 (de) 2005-11-15

Family

ID=26940161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920626T ATE309375T1 (de) 1994-05-26 1995-05-22 Onkostatin- m rezeptor

Country Status (10)

Country Link
US (7) US5783672A (de)
EP (1) EP0760857B9 (de)
JP (1) JP4392058B2 (de)
AT (1) ATE309375T1 (de)
AU (1) AU694232B2 (de)
CA (1) CA2190371C (de)
DE (1) DE69534593T2 (de)
DK (1) DK0760857T5 (de)
ES (1) ES2249770T3 (de)
WO (1) WO1995033059A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9419021D0 (en) 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
WO1996040908A1 (en) * 1995-06-07 1996-12-19 Gen-Probe Incorporated OLIGONUCLEOTIDES SPECIFIC FOR CYTOKINE SIGNAL TRANSDUCER gp130 mRNA
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
CA2237114A1 (en) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
CA2272050A1 (en) * 1996-11-20 1998-05-28 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6455040B1 (en) * 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
JP2001505060A (ja) * 1997-01-14 2001-04-17 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子受容体 ５
US6271343B1 (en) * 1997-05-01 2001-08-07 Zymogenetics, Inc. Mammalian cytokine-like receptor 5
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
DE69932247T2 (de) * 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EP2325316B8 (de) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Neues Hämopoietin Receptorprotein, NR10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2298106T3 (es) * 2000-04-21 2008-05-16 Conaris Research Institute Ag Proteinas de fusion que comprenden dos moleculas gp130 solubles.
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
EP2840089A1 (de) * 2002-01-18 2015-02-25 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
DK1961811T3 (da) 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
US7261861B2 (en) 2003-04-24 2007-08-28 Haemoscope Corporation Hemostasis analyzer and method
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
CA2604852A1 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2749571A3 (de) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Verfahren zur Behandlung von Schmerzen und Entzündungen in Nervengewebe mithilfe von IL-31RA- und OSMRb-Antagonisten
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
EP2035452B1 (de) 2006-06-22 2012-04-25 Novo Nordisk A/S Lösliche heterodimere rezeptoren und ihre verwendung
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ME03057B (de) 2007-12-07 2019-01-20 Zymogenetics Inc Für IL-31 spezifische humanisierte Antikörpermoleküle
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
TWI504609B (zh) * 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
US9475876B2 (en) 2012-05-11 2016-10-25 Wakayama Medical University Anti oncostatin M receptor beta antibody used for treating atopic dermatitis
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
WO2016046738A1 (en) 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
HRP20210737T1 (hr) 2014-12-01 2021-06-11 Ferring B.V. Primjena selektivnog inhibitora il-6-trans-signalizacije
DK3227325T3 (da) 2014-12-01 2024-07-08 Ferring Bv Sammensætninger med selektive hæmmere af il-6-trans-signalering
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120535A (en) * 1986-11-26 1992-06-09 Oncogen Oncostatin M and novel compositions having anti-neoplastic activity
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US5106731A (en) * 1988-10-21 1992-04-21 The United States Of America As Represented By The Department Of Health And Human Services Kaposi's sarcoma endothelial cells and growth factor
IL112768A (en) * 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
JP2898064B2 (ja) * 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0504291B1 (de) * 1989-12-08 1998-07-08 Bristol-Myers Squibb Company Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
IL97622A (en) * 1990-03-29 1997-06-10 Oncogen Limited Partnership Se Monoclonal antibodies that inhibit growth of kaposi's sarcoma
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
US5470824A (en) * 1991-05-31 1995-11-28 The Regents Of The University Of California Method to treat Kaposi's sarcoma
KR930703715A (ko) * 1991-11-12 1993-11-30 다쯔타 도키오 접어진 스트립 선로형 유전체 공진기 및 그것을 사용한 적층형 유전체 필터
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5284744A (en) * 1992-08-27 1994-02-08 Eastman Kodak Company Non-ultraviolet-absorbing peptizer for silver halide emulsions
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M

Also Published As

Publication number Publication date
DE69534593D1 (de) 2005-12-15
CA2190371C (en) 2010-08-31
US6010886A (en) 2000-01-04
EP0760857B9 (de) 2006-09-06
DE69534593T2 (de) 2006-08-10
AU2601695A (en) 1995-12-21
DK0760857T5 (da) 2006-10-30
WO1995033059A2 (en) 1995-12-07
WO1995033059A3 (en) 1996-01-04
JP4392058B2 (ja) 2009-12-24
US5891997A (en) 1999-04-06
EP0760857A1 (de) 1997-03-12
CA2190371A1 (en) 1995-12-07
US6524817B1 (en) 2003-02-25
AU694232B2 (en) 1998-07-16
US20050260197A1 (en) 2005-11-24
US20030109003A1 (en) 2003-06-12
JPH10501131A (ja) 1998-02-03
ES2249770T3 (es) 2006-04-01
EP0760857B1 (de) 2005-11-09
US5783672A (en) 1998-07-21
DK0760857T3 (da) 2006-01-30
US5925740A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
ATE309375T1 (de) Onkostatin- m rezeptor
ATE187982T1 (de) Cytokine antagoniste
ATE136906T1 (de) Antikörperantagonisten gegen humanes interleukin- 4
Leichtling et al. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
EA200000565A1 (ru) Цитокин-подобный полипептид-10 млекопитающих
DE69323768D1 (de) Pyrrolopyrimidine als crf antagonisten
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE69434213D1 (de) Verwendung von Zusatzstoffen in Treibstoffzusammensetzungen
NO995182L (no) Pattedyrcytokinlignende faktor 7
DE69032357D1 (de) Rekombinanter Interleukin-2-Rezeptor
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ATE132162T1 (de) Humane gammainterferonantagonisten
PT734380E (pt) 4-benzoilisoxazois e sua utilizacao como herbicidas
EA200001127A1 (ru) Бактериальные феромоны и их использование
ATE253634T1 (de) Polypeptide mit serotoninerger (5ht5a) rezeptor- aktivität, für sie kodierende nukleinsäuren und ihre verwendung
DE69433914D1 (de) Die Verwendung von Schmiermittel für Zweitaktmotor mit Direkteinspritzung
DE69230659D1 (de) Polypeptide, die an die schweren Ketten von IL-2-Rezeptoren binden können
EA199900663A1 (ru) Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны
NO912072D0 (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0760857

Country of ref document: EP

REN Ceased due to non-payment of the annual fee